Moderna (MRNA) Cash & Equivalents (2017 - 2026)

Moderna (MRNA) has 10 years of Cash & Equivalents data on file, last reported at $1.9 billion in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 17.56% year-over-year to $1.9 billion in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 17.56% increase from a year earlier, with the FY2025 full-year figure at $2.6 billion, up 34.67% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.9 billion, down from $2.6 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for MRNA reached as high as $5.0 billion in Q1 2022 and fell as low as $1.1 billion in Q3 2025.
• Historically, Cash & Equivalents has averaged $2.6 billion across 5 years, with a median of $2.6 billion in 2025.
• Across the five-year window, Cash & Equivalents slumped 53.2% in 2022 and jumped 34.67% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $3.2 billion in 2022, then slipped by 9.3% to $2.9 billion in 2023, then slumped by 33.71% to $1.9 billion in 2024, then soared by 34.67% to $2.6 billion in 2025, then dropped by 26.47% to $1.9 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $1.9 billion in Q1 2026, $2.6 billion in Q4 2025, and $1.1 billion in Q3 2025.